Marco Investment Management’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.66M Hold
19,101
0.2% 82
2025
Q4
$2.34M Sell
19,101
-400
-2% -$48.6K 0.18% 90
2025
Q3
$2.16M Sell
19,501
-98
-0.5% -$11.1K 0.17% 89
2025
Q2
$2.17M Buy
19,599
+48
+0.2% +$5.11K 0.18% 88
2025
Q1
$2.19M Sell
19,551
-100
-0.5% -$10.3K 0.2% 85
2024
Q4
$1.82M Sell
19,651
-2,500
-11% -$225K 0.16% 89
2024
Q3
$1.86M Sell
22,151
-450
-2% -$34.3K 0.16% 88
2024
Q2
$1.55M Buy
22,601
+1,450
+7% +$96.8K 0.14% 98
2024
Q1
$1.55M Sell
21,151
-4,786
-18% -$368K 0.15% 100
2023
Q4
$2.1M Buy
25,937
+251
+1% +$19.5K 0.22% 83
2023
Q3
$1.92M Sell
25,686
-2,921
-10% -$225K 0.22% 84
2023
Q2
$2.2M Sell
28,607
-1,897
-6% -$151K 0.24% 81
2023
Q1
$2.53M Sell
30,504
-500
-2% -$41.4K 0.29% 77
2022
Q4
$2.66M Sell
31,004
-2,262
-7% -$179K 0.31% 79
2022
Q3
$2.05M Sell
33,266
-3,357
-9% -$212K 0.26% 85
2022
Q2
$2.26M Sell
36,623
-2,553
-7% -$158K 0.26% 81
2022
Q1
$2.33M Sell
39,176
-10,645
-21% -$680K 0.24% 88
2021
Q4
$3.62M Sell
49,821
-1,399
-3% -$96.4K 0.36% 73
2021
Q3
$3.58M Sell
51,220
-28,699
-36% -$2.02M 0.39% 64
2021
Q2
$5.5M Buy
79,919
+1,727
+2% +$115K 0.64% 43
2021
Q1
$5.05M Sell
78,192
-554
-0.7% -$35.7K 0.66% 42
2020
Q4
$4.59M Sell
78,746
-5,098
-6% -$308K 0.66% 45
2020
Q3
$5.3M Sell
83,844
-3,521
-4% -$244K 0.87% 37
2020
Q2
$6.72M Sell
87,365
-4,970
-5% -$381K 1.23% 29
2020
Q1
$6.9M Sell
92,335
-2,751
-3% -$190K 1.46% 20
2019
Q4
$6.18M Sell
95,086
-398
-0.4% -$25.9K 0.96% 31
2019
Q3
$6.05M Buy
95,484
+93
+0.1% +$6.08K 1.03% 31
2019
Q2
$6.45M Buy
95,391
+1
+0% +$66 1.15% 27
2019
Q1
$6.2M Sell
95,390
-6,269
-6% -$417K 1.15% 26
2018
Q4
$6.36M Sell
101,659
-101,541
-50% -$7.1M 1.26% 23
2018
Q3
$15.7M Buy
203,200
+2,362
+1% +$178K 2.23% 11
2018
Q2
$14.2M Buy
200,838
+603
+0.3% +$42.6K 2.21% 10
2018
Q1
$15.1M Sell
200,235
-2,900
-1% -$231K 2.34% 11
2017
Q4
$14.6M Buy
203,135
+10,503
+5% +$798K 2.22% 11
2017
Q3
$15.6M Buy
192,632
+4,442
+2% +$340K 2.44% 7
2017
Q2
$13.3M Buy
188,190
+6,902
+4% +$459K 2.2% 8
2017
Q1
$12.3M Buy
181,288
+44,627
+33% +$3.14M 2.09% 10
2016
Q4
$9.79M Sell
136,661
-448
-0.3% -$33.3K 1.71% 13
2016
Q3
$10.8M Buy
137,109
+30,552
+29% +$2.48M 1.95% 12
2016
Q2
$8.89M Buy
106,557
+4,952
+5% +$439K 1.65% 14
2016
Q1
$9.33K Buy
101,605
+4,701
+5% +$424K 1.35% 13
2015
Q4
$9.81M Sell
96,904
-298
-0.3% -$31K 1.82% 12
2015
Q3
$322K Sell
97,202
-2,599
-3% -$289K 0.06% 152
2015
Q2
$11.7M Sell
99,801
-649
-0.6% -$70.9K 1.95% 8
2015
Q1
$9.86M Sell
100,450
-8,450
-8% -$858K 1.71% 15
2014
Q4
$10.3M Buy
108,900
+3,650
+3% +$377K 1.29% 16
2014
Q3
$11.2M Sell
105,250
-1,650
-2% -$162K 1.55% 9
2014
Q2
$8.86M Buy
106,900
+9,450
+10% +$736K 1.69% 15
2014
Q1
$6.91M Buy
97,450
+54,350
+126% +$4.26M 1.44% 20
2013
Q4
$3.24K Sell
43,100
-4,300
-9% -$299K 0.17% 57
2013
Q3
$2.98M Sell
47,400
-5,100
-10% -$305K 0.68% 55
2013
Q2
$2.69M Buy
+52,500
New +$2.74M 0.78% 45

Other funds holding GILD

Marco Investment Management's GILD Position: Q1 2026 in Review

Marco Investment Management held its Gilead Sciences (GILD) position steady in Q1 2026 at 19,101 shares worth $2.66M. The position accounts for 0.2% of the portfolio, ranked #82.

Marco Investment Management first reported a position in GILD in Q2 2013 and has held it in 52 quarters since. The position peaked at $15.7M in Q3 2018. 2,310 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Marco Investment Management held 19,101 shares of Gilead Sciences worth $2.66M as of Q1 2026.
  • Marco Investment Management left its Gilead Sciences share count unchanged in Q1 2026.
  • Gilead Sciences made up 0.2% of Marco Investment Management's portfolio in Q1 2026, its #82 holding.
  • Marco Investment Management first reported a position in Gilead Sciences in Q2 2013 and has held it in 52 quarters since.
  • Marco Investment Management's Gilead Sciences position peaked at $15.7M in Q3 2018.
  • 2,310 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Marco Investment Management's 13F filing for Q1 2026, filed 8 May 2026.